Subscribe
T. Schneider / Shutterstock.com
23 October 2025FeaturesAmericasDaniel Muino and Charles Provine

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025   The Finnish wearable tech brand is fighting hard to fend off younger rivals, with the battleground getting bloody. Sarah Speight reports.
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025   The company’s decision to sue US customs may result in a “roadmap” to sidestep ITC orders—and patent litigators are watching, finds Marisa Woutersen.
Americas
Apple Watch revives key medtech feature after import ban
18 August 2025   Several months after a US import ban sidelined a key Apple Watch feature, the tech giant is restoring a redesigned sensor to some models.


Editor's picks

Data and delivery: Inside AI's inventorship dilemma
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

Editor's picks

Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025

More features

Less is more: patent lawyers flip the script after Amgen
End of the ‘Death Squad’? Squires puts PTAB on trial
Data and delivery: Inside AI's inventorship dilemma
Weil continues expansion with top trade secrets litigator
Top pharma, biotech, and medtech experts gather at LSPN Fall
Mitsubishi Tanabe doubles down on Radicava protection
‘All it takes is a post on Truth Social’: Is this patent reform's moment?
Novartis fails to block repackaged imports of blockbuster treatment